In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response.
Subscribe to Eagle’s Eye View
Eagle's Eye View: Your Weekly CV Update From ACC.org